Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type
Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was t...
Saved in:
Published in | Human pathology Vol. 64; pp. 118 - 127 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.06.2017
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.
•CHC-SC-CLC was commonly related to prior liver injury but not cholangiolithiasis or cholangitis.•CHC-SC-CLC demonstrated indolent growth characteristics, for example, fewer Glisson sheath invasions.•IDH1/2 mutations were detected in a third of CHC-SC-CLCs but few ICCs.•CHC-SC-CLC showed a better postresection prognosis than did ICC. |
---|---|
AbstractList | Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.
•CHC-SC-CLC was commonly related to prior liver injury but not cholangiolithiasis or cholangitis.•CHC-SC-CLC demonstrated indolent growth characteristics, for example, fewer Glisson sheath invasions.•IDH1/2 mutations were detected in a third of CHC-SC-CLCs but few ICCs.•CHC-SC-CLC showed a better postresection prognosis than did ICC. Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively;P< .001) and was more common in the right lobe (70% versus 47% and 27%;P= .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively;P= .002 andP< .001) and absence of mucous production (0 versus 77% and 96%;P< .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) orIDH2was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P< .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P= .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequentIDH1/2gene mutations, and better prognosis than did MF or non-MF ICC tumors. Summary Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 ( IDH1 ) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs ( P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs ( P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors. Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors. Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors. |
Author | Deng, Min Fan, Xiang-Shan Sun, Qi Chen, Jun He, Jian Shi, Jiong Huang, Qin Mao, Liang Tang, Min Wu, Hong-Yan Qiu, Yu-Dong |
Author_xml | – sequence: 1 givenname: Jun surname: Chen fullname: Chen, Jun organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 2 givenname: Jian surname: He fullname: He, Jian organization: Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 3 givenname: Min surname: Deng fullname: Deng, Min organization: Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 4 givenname: Hong-Yan surname: Wu fullname: Wu, Hong-Yan organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 5 givenname: Jiong surname: Shi fullname: Shi, Jiong organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 6 givenname: Liang surname: Mao fullname: Mao, Liang organization: Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 7 givenname: Qi surname: Sun fullname: Sun, Qi organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 8 givenname: Min surname: Tang fullname: Tang, Min organization: Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 9 givenname: Xiang-Shan surname: Fan fullname: Fan, Xiang-Shan email: fxs23@163.com organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 10 givenname: Yu-Dong surname: Qiu fullname: Qiu, Yu-Dong email: yudongqiu510@163.com organization: Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China – sequence: 11 givenname: Qin surname: Huang fullname: Huang, Qin organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28431889$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkt-KEzEUh4OsuN3VR1AC3njRqUlmkplBdJHiP1jwQr0OaeZkm5pJusmMS9_ExzVja4WCrHAgBL7fx-Gcc4HOfPCA0FNKFpRQ8XKzWI_9Vg3rBSO0XhCaSzxAM8pLVjRly87QjJBKFA2t63N0kdKGEEp5xR-hc9ZUJW2adoZ-Lp31VofJFFy4sVq5OY6qs_vfHCvf4T440KNTEadh7HY4GMxKrEO_sh46vIYcDxqcm5hCZ5PyNzZoFbX1oVcJ39lhncPQ4wnDBtQwRkhzfITdUYCH3RYeo4dGuQRPDu8l-vb-3dflx-L684dPy7fXheaEDUVbcUWU7lRVm1YArAxnbEVa05iqBDCioxWUnJiSAm-JVoqWLQduuFi1XLDyEr3Ye7cx3I6QBtnbNHWiPIQxSdq0lFZNxUhGn5-gmzBGn7uTtKVMiKoWZaaeHahx1UMnt9H2Ku7kn5lngO8BHUNKEcwRoUROu5UbeditnHYrCc0lcu7VSU7bQQ02-CEq6-5NX-3TkIf5w0KUSVvwGjobQQ-yC_Zew5sTg_59O8p9hx2kv7OQiUkiv0zXNx0frct8eKLJgtf_FvxHA78AWwbwOg |
CitedBy_id | crossref_primary_10_1186_s40644_023_00621_3 crossref_primary_10_1038_s41379_019_0290_0 crossref_primary_10_3390_biomedicines10081826 crossref_primary_10_3390_cancers13122871 crossref_primary_10_1002_jmri_27553 crossref_primary_10_1007_s11901_020_00556_4 crossref_primary_10_1016_j_humpath_2017_12_028 crossref_primary_10_9738_INTSURG_D_18_00002_1 crossref_primary_10_1002_hep_29789 crossref_primary_10_1016_j_critrevonc_2022_103892 crossref_primary_10_1007_s11901_018_0431_9 crossref_primary_10_1016_j_compbiomed_2022_105520 crossref_primary_10_1111_hepr_13428 crossref_primary_10_1067_j_cpsurg_2018_10_002 crossref_primary_10_1186_s13578_023_01156_7 crossref_primary_10_1186_s40792_021_01120_y crossref_primary_10_11569_wcjd_v27_i18_1114 crossref_primary_10_1016_j_hpb_2019_10_009 crossref_primary_10_4254_wjh_v16_i5_766 |
Cites_doi | 10.1002/hep.25786 10.1200/JCO.2012.41.5984 10.1016/j.humpath.2011.12.007 10.1007/s11894-011-0178-8 10.1038/modpathol.2013.241 10.1200/JCO.2011.35.6519 10.1038/onc.2012.315 10.1002/hep.24351 10.1634/theoncologist.2011-0386 10.1245/s10434-014-3582-0 10.1007/s00595-014-1031-0 10.1016/j.surg.2008.11.010 10.1097/PAS.0000000000000579 10.1002/1097-0142(195907/08)12:4<753::AID-CNCR2820120420>3.0.CO;2-L 10.1002/hep.25595 10.1002/jhbp.154 10.1097/PAS.0b013e31827332b0 10.1097/00000478-199512000-00007 10.1016/j.jhep.2013.02.013 10.1002/hep.22238 10.1038/nature13441 |
ContentType | Journal Article |
Copyright | 2017 Copyright © 2017. Published by Elsevier Inc. Copyright Elsevier Limited Jun 1, 2017 |
Copyright_xml | – notice: 2017 – notice: Copyright © 2017. Published by Elsevier Inc. – notice: Copyright Elsevier Limited Jun 1, 2017 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
DOI | 10.1016/j.humpath.2017.01.016 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-8392 |
EndPage | 127 |
ExternalDocumentID | 28431889 10_1016_j_humpath_2017_01_016 S0046817717301168 1_s2_0_S0046817717301168 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQOH AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI CAG COF DU5 EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDY HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OG0 OS0 OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSZ SV3 T5K UGJ UHS UNMZH UV1 WUQ X7M Z5R ZGI ~G- 3V. 7X7 8FI AACTN AFCTW AFKRA AFKWA AJOXV AMFUW AZQEC BENPR FYUFA GUQSH M1P M2O RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
ID | FETCH-LOGICAL-c502t-945a0acda47f96eebf522b09f8f43eef6d14e350f31e590caa1395e5f56b95623 |
IEDL.DBID | .~1 |
ISSN | 0046-8177 1532-8392 |
IngestDate | Thu Jul 10 23:49:35 EDT 2025 Fri Jul 25 05:13:46 EDT 2025 Wed Feb 19 02:41:09 EST 2025 Tue Jul 01 02:24:23 EDT 2025 Thu Apr 24 23:08:20 EDT 2025 Fri Feb 23 02:24:39 EST 2024 Tue Feb 25 19:55:52 EST 2025 Tue Aug 26 16:56:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Hepatic tumors Cholangiolocellular carcinoma Isocitrate dehydrogenase Bile ducts Cholangiocarcinoma |
Language | English |
License | Copyright © 2017. Published by Elsevier Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c502t-945a0acda47f96eebf522b09f8f43eef6d14e350f31e590caa1395e5f56b95623 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
PMID | 28431889 |
PQID | 1912664763 |
PQPubID | 105547 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1891148420 proquest_journals_1912664763 pubmed_primary_28431889 crossref_primary_10_1016_j_humpath_2017_01_016 crossref_citationtrail_10_1016_j_humpath_2017_01_016 elsevier_sciencedirect_doi_10_1016_j_humpath_2017_01_016 elsevier_clinicalkeyesjournals_1_s2_0_S0046817717301168 elsevier_clinicalkey_doi_10_1016_j_humpath_2017_01_016 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-06-01 |
PublicationDateYYYYMMDD | 2017-06-01 |
PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Philadelphia |
PublicationTitle | Human pathology |
PublicationTitleAlternate | Hum Pathol |
PublicationYear | 2017 |
Publisher | Elsevier Inc Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
References | Tyson, El-Serag (bb0010) 2011; 54 Edge, Byrd, Compton, Fritz, Greene, Trotti (bb0105) 2010 Ariizumi, Yamamoto (bb0075) 2015; 45 Nakanuma, Curado, Franceschi (bb0060) 2010 Batts, Ludwig (bb0110) 1995; 19 de Jong, Nathan, Sotiropoulos (bb0020) 2011; 9 Wang, Li, Xia (bb0015) 2013; 31 Aishima, Oda (bb0080) 2015; 22 Charbel, Al-Kawas (bb0005) 2011; 13 Steiner, Higginson (bb0025) 1959; 12 Komuta, Spee, Vander (bb0035) 2008; 47 Theise, Nakashima, Park, Nakanuma (bb0040) 2010 Ariizumi, Kotera, Katagiri (bb0050) 2014; 21 Rocha, Lee, Katabi (bb0070) 2012; 56 Wang, Dong, Zhang (bb0120) 2013; 32 Akiba, Nakashima, Hattori (bb0115) 2013; 37 Liau, Tsai, Yuan, Chang, Lee, Jeng (bb0030) 2014; 27 Shimada, Sano, Nara (bb0065) 2009; 145 Shibahara, Hayashi, Misumi (bb0045) 2016; 40 Saha, Parachoniak, Ghanta (bb0095) 2014; 513 Iavarone, Piscaglia, Vavassori (bb0100) 2013; 58 Komuta, Govaere, Vandecaveye (bb0055) 2012; 55 Borger, Tanabe, Fan (bb0085) 2012; 17 Kipp, Voss, Kerr (bb0090) 2012; 43 Saha (10.1016/j.humpath.2017.01.016_bb0095) 2014; 513 Rocha (10.1016/j.humpath.2017.01.016_bb0070) 2012; 56 Aishima (10.1016/j.humpath.2017.01.016_bb0080) 2015; 22 Charbel (10.1016/j.humpath.2017.01.016_bb0005) 2011; 13 Ariizumi (10.1016/j.humpath.2017.01.016_bb0075) 2015; 45 Wang (10.1016/j.humpath.2017.01.016_bb0015) 2013; 31 Shimada (10.1016/j.humpath.2017.01.016_bb0065) 2009; 145 Liau (10.1016/j.humpath.2017.01.016_bb0030) 2014; 27 Iavarone (10.1016/j.humpath.2017.01.016_bb0100) 2013; 58 Akiba (10.1016/j.humpath.2017.01.016_bb0115) 2013; 37 Steiner (10.1016/j.humpath.2017.01.016_bb0025) 1959; 12 Komuta (10.1016/j.humpath.2017.01.016_bb0055) 2012; 55 Batts (10.1016/j.humpath.2017.01.016_bb0110) 1995; 19 Theise (10.1016/j.humpath.2017.01.016_bb0040) 2010 Wang (10.1016/j.humpath.2017.01.016_bb0120) 2013; 32 de Jong (10.1016/j.humpath.2017.01.016_bb0020) 2011; 9 Nakanuma (10.1016/j.humpath.2017.01.016_bb0060) 2010 Kipp (10.1016/j.humpath.2017.01.016_bb0090) 2012; 43 Tyson (10.1016/j.humpath.2017.01.016_bb0010) 2011; 54 Ariizumi (10.1016/j.humpath.2017.01.016_bb0050) 2014; 21 Komuta (10.1016/j.humpath.2017.01.016_bb0035) 2008; 47 Borger (10.1016/j.humpath.2017.01.016_bb0085) 2012; 17 Shibahara (10.1016/j.humpath.2017.01.016_bb0045) 2016; 40 Edge (10.1016/j.humpath.2017.01.016_bb0105) 2010 |
References_xml | – volume: 43 start-page: 1552 year: 2012 end-page: 1558 ident: bb0090 article-title: Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma publication-title: H – volume: 31 start-page: 1188 year: 2013 end-page: 1195 ident: bb0015 article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy publication-title: J Clin Oncol – volume: 513 start-page: 110 year: 2014 end-page: 114 ident: bb0095 article-title: Mutant publication-title: Nature – volume: 37 start-page: 496 year: 2013 end-page: 505 ident: bb0115 article-title: Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification publication-title: Am J Surg Pathol – volume: 47 start-page: 1544 year: 2008 end-page: 1556 ident: bb0035 article-title: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin publication-title: Hepatology – volume: 54 start-page: 173 year: 2011 end-page: 184 ident: bb0010 article-title: Risk factors for cholangiocarcinoma publication-title: Hepatology – volume: 21 start-page: S451 year: 2014 end-page: S458 ident: bb0050 article-title: Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy publication-title: Ann Surg Oncol – volume: 12 start-page: 753 year: 1959 end-page: 759 ident: bb0025 article-title: Cholangiolocellular carcinoma of the liver publication-title: Cancer – volume: 40 start-page: 608 year: 2016 end-page: 616 ident: bb0045 article-title: Clinicopathologic characteristics of hepatocellular carcinoma with reactive ductule-like components, a subset of liver cancer currently classified as combined hepatocellular-cholangiocarcinoma with stem cell features, typical subtype publication-title: Am J Surg Pathol – volume: 45 start-page: 682 year: 2015 end-page: 687 ident: bb0075 article-title: Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis publication-title: Surg Today – volume: 55 start-page: 1876 year: 2012 end-page: 1888 ident: bb0055 article-title: Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes publication-title: Hepatology – volume: 56 start-page: 1352 year: 2012 end-page: 1360 ident: bb0070 article-title: Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas publication-title: Hepatology – volume: 19 start-page: 1409 year: 1995 end-page: 1417 ident: bb0110 article-title: Chronic hepatitis: an update on terminology and reporting publication-title: Am J Surg Pathol – volume: 145 start-page: 411 year: 2009 end-page: 416 ident: bb0065 article-title: Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement publication-title: Surgery – volume: 17 start-page: 72 year: 2012 end-page: 79 ident: bb0085 article-title: Frequent mutation of isocitrate dehydrogenase ( publication-title: Oncologist – start-page: 217 year: 2010 end-page: 224 ident: bb0060 article-title: Intrahepatic cholangiocarcinoma publication-title: WHO classification of tumours of the digestive system – volume: 32 start-page: 3091 year: 2013 end-page: 3100 ident: bb0120 article-title: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas publication-title: Oncogene – volume: 9 start-page: 3140 year: 2011 end-page: 3145 ident: bb0020 article-title: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment publication-title: J Clin Oncol – start-page: 247 year: 2010 end-page: 254 ident: bb0105 article-title: AJCC cancer staging manual – volume: 13 start-page: 182 year: 2011 end-page: 187 ident: bb0005 article-title: Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis publication-title: Curr Gastroenterol Rep – start-page: 225 year: 2010 end-page: 227 ident: bb0040 article-title: Combined hepatocellular-cholangiocarcinoma publication-title: WHO classification of tumours of the digestive system – volume: 22 start-page: 94 year: 2015 end-page: 100 ident: bb0080 article-title: Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type publication-title: J Hepatobiliary Pancreat Sci – volume: 27 start-page: 1163 year: 2014 end-page: 1173 ident: bb0030 article-title: Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features publication-title: Mod Pathol – volume: 58 start-page: 1188 year: 2013 end-page: 1193 ident: bb0100 article-title: Contrast-enhanced CT scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis publication-title: J Hepatol – volume: 56 start-page: 1352 year: 2012 ident: 10.1016/j.humpath.2017.01.016_bb0070 article-title: Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas publication-title: Hepatology doi: 10.1002/hep.25786 – volume: 31 start-page: 1188 year: 2013 ident: 10.1016/j.humpath.2017.01.016_bb0015 article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy publication-title: J Clin Oncol doi: 10.1200/JCO.2012.41.5984 – volume: 43 start-page: 1552 year: 2012 ident: 10.1016/j.humpath.2017.01.016_bb0090 article-title: Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma publication-title: Hum Pathol doi: 10.1016/j.humpath.2011.12.007 – volume: 13 start-page: 182 year: 2011 ident: 10.1016/j.humpath.2017.01.016_bb0005 article-title: Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-011-0178-8 – volume: 27 start-page: 1163 year: 2014 ident: 10.1016/j.humpath.2017.01.016_bb0030 article-title: Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features publication-title: Mod Pathol doi: 10.1038/modpathol.2013.241 – volume: 9 start-page: 3140 year: 2011 ident: 10.1016/j.humpath.2017.01.016_bb0020 article-title: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.6519 – volume: 32 start-page: 3091 year: 2013 ident: 10.1016/j.humpath.2017.01.016_bb0120 article-title: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas publication-title: Oncogene doi: 10.1038/onc.2012.315 – volume: 54 start-page: 173 year: 2011 ident: 10.1016/j.humpath.2017.01.016_bb0010 article-title: Risk factors for cholangiocarcinoma publication-title: Hepatology doi: 10.1002/hep.24351 – volume: 17 start-page: 72 year: 2012 ident: 10.1016/j.humpath.2017.01.016_bb0085 article-title: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping publication-title: Oncologist doi: 10.1634/theoncologist.2011-0386 – volume: 21 start-page: S451 issue: Suppl. 3 year: 2014 ident: 10.1016/j.humpath.2017.01.016_bb0050 article-title: Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-3582-0 – volume: 45 start-page: 682 year: 2015 ident: 10.1016/j.humpath.2017.01.016_bb0075 article-title: Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis publication-title: Surg Today doi: 10.1007/s00595-014-1031-0 – volume: 145 start-page: 411 year: 2009 ident: 10.1016/j.humpath.2017.01.016_bb0065 article-title: Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement publication-title: Surgery doi: 10.1016/j.surg.2008.11.010 – volume: 40 start-page: 608 year: 2016 ident: 10.1016/j.humpath.2017.01.016_bb0045 article-title: Clinicopathologic characteristics of hepatocellular carcinoma with reactive ductule-like components, a subset of liver cancer currently classified as combined hepatocellular-cholangiocarcinoma with stem cell features, typical subtype publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000579 – start-page: 225 year: 2010 ident: 10.1016/j.humpath.2017.01.016_bb0040 article-title: Combined hepatocellular-cholangiocarcinoma – volume: 12 start-page: 753 year: 1959 ident: 10.1016/j.humpath.2017.01.016_bb0025 article-title: Cholangiolocellular carcinoma of the liver publication-title: Cancer doi: 10.1002/1097-0142(195907/08)12:4<753::AID-CNCR2820120420>3.0.CO;2-L – volume: 55 start-page: 1876 year: 2012 ident: 10.1016/j.humpath.2017.01.016_bb0055 article-title: Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes publication-title: Hepatology doi: 10.1002/hep.25595 – start-page: 217 year: 2010 ident: 10.1016/j.humpath.2017.01.016_bb0060 article-title: Intrahepatic cholangiocarcinoma – volume: 22 start-page: 94 year: 2015 ident: 10.1016/j.humpath.2017.01.016_bb0080 article-title: Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type publication-title: J Hepatobiliary Pancreat Sci doi: 10.1002/jhbp.154 – start-page: 247 year: 2010 ident: 10.1016/j.humpath.2017.01.016_bb0105 – volume: 37 start-page: 496 year: 2013 ident: 10.1016/j.humpath.2017.01.016_bb0115 article-title: Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e31827332b0 – volume: 19 start-page: 1409 year: 1995 ident: 10.1016/j.humpath.2017.01.016_bb0110 article-title: Chronic hepatitis: an update on terminology and reporting publication-title: Am J Surg Pathol doi: 10.1097/00000478-199512000-00007 – volume: 58 start-page: 1188 year: 2013 ident: 10.1016/j.humpath.2017.01.016_bb0100 article-title: Contrast-enhanced CT scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis publication-title: J Hepatol doi: 10.1016/j.jhep.2013.02.013 – volume: 47 start-page: 1544 year: 2008 ident: 10.1016/j.humpath.2017.01.016_bb0035 article-title: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin publication-title: Hepatology doi: 10.1002/hep.22238 – volume: 513 start-page: 110 year: 2014 ident: 10.1016/j.humpath.2017.01.016_bb0095 article-title: Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer publication-title: Nature doi: 10.1038/nature13441 |
SSID | ssj0011545 |
Score | 2.3369002 |
Snippet | Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this... Summary Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 118 |
SubjectTerms | Adult Aged Aged, 80 and over Bile Bile Duct Neoplasms - diagnosis Bile Duct Neoplasms - diagnostic imaging Bile Duct Neoplasms - genetics Bile Duct Neoplasms - pathology Bile ducts Biomarkers, Tumor - genetics Biopsy Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - pathology Cell Proliferation Cholangiocarcinoma Cholangiocarcinoma - diagnosis Cholangiocarcinoma - diagnostic imaging Cholangiocarcinoma - genetics Cholangiocarcinoma - pathology Cholangiolocellular carcinoma Classification Dehydrogenases Digestive system DNA Mutational Analysis Female Hepatectomy Hepatic tumors Hepatitis Hepatology Humans Immunohistochemistry Isocitrate dehydrogenase Isocitrate Dehydrogenase - genetics Kaplan-Meier Estimate Laboratories Liver cancer Liver Neoplasms - diagnosis Liver Neoplasms - diagnostic imaging Liver Neoplasms - genetics Liver Neoplasms - pathology Lymphatic system Male Medical prognosis Medical records Middle Aged Molecular Diagnostic Techniques Mutation Neoplasm Invasiveness Neoplasms, Complex and Mixed - diagnosis Neoplasms, Complex and Mixed - diagnostic imaging Neoplasms, Complex and Mixed - genetics Neoplasms, Complex and Mixed - pathology Neoplastic Stem Cells - pathology Pathology Patients Predictive Value of Tests Proportional Hazards Models Stem cells Studies Surgery Time Factors Tomography, X-Ray Computed Treatment Outcome Tumor Burden Tumorigenesis Tumors Viral infections |
Title | Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0046817717301168 https://www.clinicalkey.es/playcontent/1-s2.0-S0046817717301168 https://dx.doi.org/10.1016/j.humpath.2017.01.016 https://www.ncbi.nlm.nih.gov/pubmed/28431889 https://www.proquest.com/docview/1912664763 https://www.proquest.com/docview/1891148420 |
Volume | 64 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcQSNNepsG-ugHypD02bZzYTvyIEKhQwcM0NN4sJzmPIkhQW173d-zP3V3iBE1jYkKqVKW9i6O7y_ln-z4Y-4IQVEMCcZQhdoikQF3kZSWitBQl5CAqV9A-5Nm5nl3I00t1ucEO-1wYCqsMvr_z6a23Dr9MgzSnd4sF5fhKnYuMjpHpNIESfqXMyMonP4cwD6o203UxkDoi6ocsnun15ApFhkCLIryytnontT1_fH76F_5s56Hj1-xVAJD8oHvGbbYB9Q57cRaOyN-wX12lz4ZG7B3bmC9dteiuxtzVFb_tu-Lytr4sbzxPUo5CwIUyVPwKJ6l1Q5v6RBO1C-D6xwLnvSWOQiFFnDZwOVWB5kTGPbQVQldjPhDfDDfgtNH7ll0cH307nEWh_UJUqjhZR0YqF7uycjLzRgMUHrFaERufe5kCeF0JCamKfSpAmbh0DtGkAuWVLgzBqndss25q-MB4WkCiq8IA0kpTmFxlvt0_QTCXIiQdMdkL3ZahNjm1yLixfRDatQ26sqQrGwv86BGbDGx3XXGOpxh0r1HbZ56ir7Q4fTzFmD3GCKvwxq-ssKvExvYvqxyxfOD8w7D_Z9Dd3ujswzhGIKZCO09H7PPwN_oEUqmroblHmtzQMlcmKNj3nbEO8kE4gm48Nx-f_1yf2Eu66gLmdtnmenkPewjN1sV---7ts62Dk_nsnL7nX7_PfwOQBDzX |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fT9swELdYkba9TPvLytjmSXtsaJzYTvyI0FAZtE8g8WY5yXkUsQS15bvs43KXOEHTmJgm5aXJXR3dOXc_353PjH1FCKohgTjKEDtEUqAu8rISUVqKEnIQlSsoDjlf6Nm5_H6hLrbYYb8Xhsoqg-3vbHprrcOdaZDm9Ga5pD2-UuciozQyZRPyJ2ybulOpEds-OD6ZLYZkAqGELtGsI2K438gzvdq_RKkh1qIir6xt4Eknnz_sov4GQVtXdPSSvQgYkh90r_mKbUH9mj2dhyz5G_ara_bZ0Ii9bZvwlauW3a8Jd3XFf_YH4_K2xSxvPE9SjnLAtTJU_BL91KahuD7RRO0auP6xRNe3wlGoqohTDJdTI2hOZNxD2yR0PeED8fXwB5xivW_Z-dG3s8NZFE5giEoVJ5vISOViV1ZOZt5ogMIjXCti43MvUwCvKyEhVbFPBSgTl84hoFSgvNKFIWT1jo3qpob3jKcFJLoqDCCtNIXJVebbEAriuRRR6ZjJXui2DO3J6ZSMa9vXoV3ZoCtLurKxwEuP2f7AdtP153iMQfcatf3mUzSXFj3IY4zZQ4ywDh_92gq7Tmxs_5iYY5YPnL_N7X8ZdK-fdPZ-HCMQVkn0DGP2ZXiMZoFU6mpobpEmN7TSlQkKdqebrIN8EJGgJc_N7v-_12f2bHY2P7Wnx4uTD-w5Penq5_bYaLO6hY-I1DbFp_Al3gFWLD3l |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinicopathological%2C+radiologic%2C+and+molecular+study+of+23+combined+hepatocellular-cholangiocarcinomas+with+stem+cell+features%2C+cholangiolocellular+type&rft.jtitle=Human+pathology&rft.au=Chen%2C+Jun&rft.au=He%2C+Jian&rft.au=Deng%2C+Min&rft.au=Wu%2C+Hong-Yan&rft.date=2017-06-01&rft.eissn=1532-8392&rft.volume=64&rft.spage=118&rft_id=info:doi/10.1016%2Fj.humpath.2017.01.016&rft_id=info%3Apmid%2F28431889&rft.externalDocID=28431889 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00468177%2Fcov200h.gif |